Business Wire

SailPoint Unveils the New Frontiers In Identity Governance at Navigate ‘18

Share

SailPoint Technologies Holdings, Inc. (NYSE: SAIL), the leader in enterprise identity governance, kicked off a sold-out Navigate ‘18 by unveiling new frontiers in identity governance. As organizations struggle to keep pace with the constantly evolving security and compliance landscape while undertaking their digital transformation, identity governance must embrace three new frontiers. These frontiers span users, applications and data.

“Data breaches and compliance aren’t the only challenges we’re facing as an industry. The very nature of our business is changing. The pressure to digitize the enterprise is growing in importance as businesses fight to keep their competitive edge and to continuously deliver value to their customers,” said Mark McClain, CEO and co-founder for SailPoint. “Our world has changed in a profound way. Both user and application populations are growing and changing. Data is exploding and continues to evolve into new formats and move into new locations. Identity must evolve to tackle this new world in which we live, governing access across all users, all applications and all data. SailPoint is pushing the limits of these three new identity frontiers.”

The New Identity Frontiers

SailPoint believes there are three identity frontiers that organizations need to embrace as they chart their identity course today:

  • The User Frontier: Expanding Identities Beyond Humans: Enterprise identity governance programs have traditionally focused on three primary users: employees, contractors and partners. In the new business world, non-human users –such as software bots and technology like RPA (Robotic Process Automation) – introduce a new identity type. Modern enterprises must rethink identities beyond humans, understanding how these non-human entities interact with enterprise applications and data while applying proper governance controls.
  • The Application Frontier: Scaling to Today’s Realities: Enterprises today manage hundreds of applications that drive their business forward. This includes an increasing number of SaaS applications alongside traditional legacy applications. As business users accelerate the need for new applications, identity governance must also evolve, making it easier to onboard new applications to more nimbly enable the business.
  • The Data Frontier: Securing Access to Data in Files: In the past, most sensitive data was stored in applications and databases such as CRM, HR, and financial systems. Today, end users are downloading, extracting and copying that data into files and then storing that data in file shares, like SharePoint, and cloud storage systems, such as Box and Google Drive, often leaving the data largely unprotected. This opens up a huge area of exposure for organizations that must be addressed with identity governance, making data the third, and perhaps most critical, new frontier in identity.

“As technology and innovation are changing the way we work, the nature of business users is evolving, while the volume of applications and data are furiously increasing. SailPoint is at the forefront of developing innovative ways of providing comprehensive identity governance to secure the digital identities of all users across all applications and all data,” said McClain. “This is our vision and the only path forward for global enterprises today.”

To make SailPoint’s vision for identity governance a reality, SailPoint previewed new technology innovations at Navigate ‘18 across the three frontiers, including unveiling the latest release of SecurityIQ 6.0, which extends identity governance to data stored in files like spreadsheets and documents. For more on SecurityIQ 6.0, please reference SailPoint’s SecurityIQ 6.0 Delivers Identity Governance for Files from the Data Center or the Cloud.

SailPoint: The Power of Identity™

SailPoint, the leader in enterprise identity governance, brings the Power of Identity to customers around the world. SailPoint’s open identity platform gives organizations the power to enter new markets, scale their workforces, embrace new technologies, innovate faster and compete on a global basis. As both an industry pioneer and market leader in identity governance, SailPoint delivers security, operational efficiency and compliance to enterprises with complex IT environments. SailPoint’s customers are among the world’s largest companies in a wide range of industries, including: 7 of the top 15 banks, 4 of the top 6 healthcare insurance and managed care providers, 9 of the top 15 property and casualty insurance providers, 5 of the top 15 pharmaceutical companies, and 11 of the largest 15 federal agencies.

Stay up-to-date on SailPoint by following us on Twitter and LinkedIn and by subscribing to the SailPoint blog.

SailPoint, the SailPoint logo, IdentityIQ, IdentityNow, IdentityAI, SecurityIQ and all techniques are trademarks or registered trademarks of SailPoint Technologies Holdings, Inc. in the U.S. and/or other countries. All other products or services are trademarks of their respective companies.

Contact information

SailPoint Technologies Holdings, Inc.
Jessica Sutera, 978-278-5411
Jessica.Sutera@sailpoint.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu